ArticleJournal of endocrinological investigation2026
Lactobacillus gasseri alleviates type 2 diabetes via modulation of gut microbiota-host metabolic networks.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by insulin resistance, dyslipidemia and inflammation. Although probiotics have shown potential in improving glycemic control in T2DM, the systemic mechanisms underlying their therapeutic effects remain largely unclear.
methodsA high glucose-induced insulin-resistant zebrafish model was established to explore the interventional effects of Lactobacillus gasseri GDMCC AM63 (L. gasseri). Biochemical assays combined with untargeted metabolomics were used to comprehensively evaluate the efficacy of L. gasseri intervention.
resultsL. gasseri intervention significantly reduced fasting blood glucose levels, inhibited the expression of pro-inflammatory cytokines (tnfα and il-6), and upregulated the anti-inflammatory cytokine il-10. Metabolomic profiling identified 210 shared annotated DAMs in pairwise comparisons (T2DM_vs_control (Ctrl) group, and L. gasseri intervention (LG)_vs_T2DM group), which were mainly involved in lipid, amino acid, and carbohydrate metabolism. Pathway enrichment analysis showed significant enrichment of glycerophospholipid, fructose-mannose, pentose phosphate, riboflavin, and linoleic acid metabolic pathways. After FDR correction, 27 shared annotated significant DAMs (SDAMs) were identified. Integrated metabolomics and network pharmacology analysis suggested that L. gasseri may exert a therapeutic effect on T2DM by indirectly regulating signaling pathways such as PI3K/Akt and JAK/STAT. Randomforest analysis highlighted 18R-Hepe and Azii as potential metabolic biomarkers with predictive value.
conclusionThis study systematically investigated the metabolic regulatory mechanisms by which L. gasseri ameliorates T2DM, providing experimental evidence to support its potential as an effective interventional strategy for improving insulin resistance and related metabolic dysfunctions.
Indexed as
Identifiers
42371341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.